+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bioconjugation Market by Bioconjugation Type (Oligonucleotide Bioconjugation, Peptide Bioconjugation, Polymer Bioconjugation), Offering (Reagents & Kits, Services), Technique, Type, End User, Applications, Therapeutic Areas - Global Forecast 2025-2030- Product Image
Bioconjugation Market by Bioconjugation Type (Oligonucleotide Bioconjugation, Peptide Bioconjugation, Polymer Bioconjugation), Offering (Reagents & Kits, Services), Technique, Type, End User, Applications, Therapeutic Areas - Global Forecast 2025-2030- Product Image
Sale

Bioconjugation Market by Bioconjugation Type (Oligonucleotide Bioconjugation, Peptide Bioconjugation, Polymer Bioconjugation), Offering (Reagents & Kits, Services), Technique, Type, End User, Applications, Therapeutic Areas - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 196 Pages
  • March 2025
  • Region: Global
  • 360iResearch™
  • ID: 6021460
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Bioconjugation Market grew from USD 8.13 billion in 2023 to USD 9.06 billion in 2024. It is expected to continue growing at a CAGR of 12.19%, reaching USD 18.20 billion by 2030.

Bioconjugation has emerged as a cornerstone in modern biomedical innovation, intertwining the realms of chemistry and biology to create targeted therapeutics and advanced diagnostic solutions. Over the recent years, the process of linking biomolecules has transitioned from a niche laboratory procedure into a pivotal technology that underpins transformative healthcare solutions. This report introduces the nuances of the bioconjugation process while emphasizing its expanding relevance in both research and applied sciences.

In an environment where science meets technology, the integration of chemical moieties with biological substrates enables the development of highly specific drugs, imaging agents, and delivery systems. Researchers and industry experts now benefit from improved product versatility and enhanced performance driven by precise molecular engineering. This expansive field is characterized by a blend of traditional techniques and breakthrough innovations, making it essential for stakeholders to remain informed about the latest trends and developments. As we journey through an analytical overview of market segmentation, regional distribution, and major industry players, readers are provided with a comprehensive lens through which to evaluate future opportunities and strategic growth areas in bioconjugation.

Transformative Shifts in the Bioconjugation Landscape

Innovation in bioconjugation is no longer confined to incremental advancements; the field is experiencing transformative shifts that reframe long-standing paradigms in drug development and diagnostic research. Recent breakthroughs have accelerated the transition from conventional conjugation techniques to more sophisticated methodologies that guarantee higher selectivity and efficiency. Increasing regulatory emphasis on quality and reproducibility has necessitated the adoption of advanced protocols. These shifts not only optimize product performance but also reduce critical timelines in therapy development.

Concurrent technological improvements, such as enhanced analytical methods and automation, have streamlined the bioconjugation process. This evolution is influencing the manufacturing of complex drug entities and facilitating the rapid development of targeted therapies. The industry is witnessing a trend where precision-based chemistry integrates with innovative biotechnologies. This synthesis is empowering companies to address unmet clinical needs and shape strategies that align with evolving healthcare standards. Stakeholders are thus called to reconsider traditional models and invest in robust, scalable processes while embracing a future where bioconjugation occupies a central role in the creation of next-generation biomedical solutions.

Key Segmentation Insights: Dissecting the Market Components

The evolving bioconjugation market is segmented into multiple dimensions that provide a granular understanding of the industry landscape. In the domain of bioconjugation type, market analysis covers several core areas including oligonucleotide, peptide, polymer, and protein conjugation. Among these, oligonucleotide bioconjugation is further analyzed through its application to both double-stranded and single-stranded oligonucleotides, revealing the nuanced performance differences that influence both efficacy and stability.

Further segmentation is evident when evaluating market offerings. The industry distinguishes between reagents and kits as well as a spectrum of services. The services segment, in particular, is dissected into ADC process development, analytical development, drug substance manufacturing, early development bioconjugate services, payload and linker manufacturing, and targeting agent or carrier protein services, each contributing uniquely to overall market growth. Equally significant is the segmentation based on techniques where amide bond formation, bio-orthogonal reactions, click chemistry, enzymatic methods, and thiol-maleimide coupling define the methodological spectrum.

Additionally, differentiation based on the nature of bioconjugates is undertaken by distinguishing between natural and synthetic variants. End-user segmentation further refines the market by including academic and research institutions, biotechnology companies, contract research organizations, and pharmaceutical companies. The application landscape spans diagnostics, research and development, and therapeutic areas with the latter elaborating on sub-categories such as antibiotics, monoclonal antibodies, and vaccines. Finally, therapeutic areas such as cardiovascular disorders, immunology, infectious diseases, and oncology inform strategic decisions and investment priorities by showcasing where bioconjugation technologies deliver critical clinical impact.

Based on Bioconjugation Type, market is studied across Oligonucleotide Bioconjugation, Peptide Bioconjugation, Polymer Bioconjugation, and Protein Bioconjugation. The Oligonucleotide Bioconjugation is further studied across Double-Stranded Oligonucleotides and Single-Stranded Oligonucleotides.

Based on Offering, market is studied across Reagents & Kits and Services. The Services is further studied across ADC Process Development, Analytical development, Drug Substance Manufacturing, Early Development Bioconjugate Services, Payload & Linker Manufacturing, and Targeting Agent or Carrier Protein Services.

Based on Technique, market is studied across Amide Bond Formation, Bio-orthogonal Reactions, Click Chemistry, Enzymatic Methods, and Thiol-Maleimide Coupling.

Based on Type, market is studied across Natural Bioconjugates and Synthetic Bioconjugates.

Based on End User, market is studied across Academic & Research Institutions, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies.

Based on Applications, market is studied across Diagnostics, Research and Development, and Therapeutic. The Therapeutic is further studied across Antibiotics, Monoclonal Antibodies, and Vaccines.

Based on Therapeutic Areas, market is studied across Cardiovascular Disorders, Immunology, Infectious Diseases, and Oncology.

Key Regional Insights: A Global Perspective on Market Growth

The bioconjugation market is witnessing differentiated growth patterns across several geographic segments. In the Americas, robust investments in biomedical research coupled with a strong presence of regulatory agencies drive significant innovation and adoption. The region’s strategic focus on precision medicine complements ongoing efforts to integrate advanced bioconjugation techniques into therapeutic and diagnostic applications.

Across Europe, the Middle East and Africa, the emphasis lies in regulatory harmonization and public-private partnerships, fostering an environment where innovative research thrives. These regions are characterized by an amalgamation of traditional research strengths and emergent technological trends, paving the way for a seamless transition from developmental phases to clinical applications. In the Asia-Pacific, rapid industrialization and strong governmental support for research and technology have catalyzed market growth. Here, expansive research networks and a burgeoning biotech landscape are instrumental in promoting cost-effective innovations. This global terrain not only presents a mosaic of opportunity but also encourages cross-regional collaborations that propel the bioconjugation market towards unified, next-generation solutions.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights: Leaders Shaping the Future

The competitive arena in bioconjugation is defined by an assortment of industry leaders who steer innovation and set high standards for market practices. Prominent companies such as AbbVie Inc. and Abcam plc by Danaher Corporation have significantly influenced the research and development trajectories in this domain. Firms like Abzena Limited and Agilent Technologies, Inc. have pioneered advanced technologies that streamline the formation of complex bioconjugates, ensuring efficacy and scalability in production.

Other key players, including Amgen Inc., AstraZeneca PLC, and Bio-Techne Corporation, have leveraged their scientific expertise and market reach to accelerate product development and clinical translation. The dynamic involvement of Biocon Limited, Boehringer Ingelheim GmbH, and Bristol-Myers Squibb Company further underscores the collaborative spirit that is steadily transforming bioconjugation practices. Additionally, enterprises such as Charles River Laboratories International, Inc., Eli Lilly and Company, and F. Hoffmann-La Roche AG maintain a strategic presence in innovation clusters worldwide. This narrative is complemented by the contributions of GlaxoSmithKline plc, Innovagen AB, Johnson & Johnson Services Inc, Lonza Group AG, Merck KGaA, Pfizer Inc., and Sanofi S.A., who continue to push the envelope in research and commercialization. The engagement of Sartorius AG, Sorrento Therapeutics, Inc., Sutro Biopharma, Inc., Thermo Fisher Scientific Inc., and WuXi AppTec Co., Ltd. further embodies the spirit of relentless advancement and commitment to quality that defines this market segment.

The report delves into recent significant developments in the Bioconjugation Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Abcam plc by Danaher Corporation, Abzena Limited, Agilent Technologies, Inc., Amgen Inc., AstraZeneca PLC, Bio-Techne Corporation, Biocon Limited, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Charles River Laboratories International, Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Innovagen AB, Johnson & Johnson Services Inc, Lonza Group AG, Merck KGaA, Pfizer Inc., Sanofi S.A., Sartorius AG, Sorrento Therapeutics, Inc., Sutro Biopharma, Inc., Thermo Fisher Scientific Inc., and WuXi AppTec Co., Ltd.

Actionable Recommendations for Industry Leaders: Strategic Pathways for Growth

Industry leaders are encouraged to harness emerging trends and adopt an integrated approach that blends advanced technologies with operational excellence. Continuous investment in research and development is critical, and expanding collaborative networks can pave the way for innovative therapeutic applications. Establishing partnerships with academic and research institutions, biotechnology companies, and contract research organizations can provide access to diverse technical expertise that is essential for refining bioconjugation protocols.

Leaders should focus on consolidating their supply chain management while also exploring strategic alliances to mitigate risks and enhance market responsiveness. Implementation of state-of-the-art analytical tools and automation platforms can significantly streamline development cycles, thereby ensuring faster time-to-market for next-generation products. Additionally, investing in training and development initiatives for technical teams will foster an environment of operational excellence and continuous improvement. Such proactive measures will not only yield competitive advantages but also position companies at the forefront of innovation in a market where precision and accuracy are paramount.

Embracing digital transformation and leveraging real-time data analytics will further bolster decision-making processes, enabling companies to adapt swiftly to emerging market dynamics. In summary, a robust strategic framework centered on innovation, agile operational practices, and strong collaborative ties remains essential for capitalizing on the transformative trends in bioconjugation.

Charting the Future of Bioconjugation

In summarizing the current state and future outlook of the bioconjugation market, it is evident that the interplay of innovative technology, strategic execution, and comprehensive segmentation is propelling the industry to new heights. The evolution from traditional conjugation methods to precision-engineered solutions has redefined therapeutic development and diagnostic accuracy. A deep understanding of the segmented market - from bioconjugation types and techniques to offerings and end-user categories - enables stakeholders to navigate an ecosystem that is as complex as it is dynamic.

Moreover, the regional insights highlight a convergence of diverse market drivers that collectively foster robust growth. With globally recognized industry leaders setting a high bar for research and commercial execution, the future of bioconjugation is underscored by a commitment to quality, innovation, and strategic foresight. In this continuously evolving landscape, companies that adapt proactively and invest strategically are well-positioned to capitalize on emerging opportunities and drive sustainable growth.

This comprehensive assessment serves as a call for decision-makers to harness the full potential of bioconjugation, catalyzing breakthroughs that promise transformative impacts on patient care and scientific research alike.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Surge in the use of biotherapeutics & antibody-drug conjugates (ADC)
5.1.2. Restraints
5.1.2.1. Cost-intensive nature of bioconjugation research and the initial investment for advanced research equipment
5.1.3. Opportunities
5.1.3.1. Technological advancements for synthesizing the bioconjugates
5.1.3.2. Growing investment from public & private sector in bioconjugation capabilities
5.1.4. Challenges
5.1.4.1. Concerns associated with maintaining consistency and quality control in bioconjugate manufacturing
5.2. Market Segmentation Analysis
5.2.1. Therapeutic Areas: Significant benefits of bioconjugation in cardiovascular owing to improved delivery and efficacy of therapeutic
5.2.2. Bioconjugation Type: Growing significance of single-stranded oligonucleotides due to enhanced versatility in therapeutic interventions
5.2.3. Offering: Rising potential of ADC process development services owing to intricate design and optimization of conjugation processes
5.2.4. Technique: Increased adoption of amide bond formation technique due to reliability and the strength of the resulting conjugates
5.2.5. Type: Growing significance of synthetic bioconjugates due to their stability and customization capabilities
5.2.6. End User: Emerging incorporation of bioconjugation in biotechnology companies to enhance the efficacy and specificity of their biopharmaceutical products
5.2.7. Applications: Proliferation of bioconjugation in cancer diagnostics owing to precise identification of cancerous cells and tumor-specific antigens
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Bioconjugation Market, by Bioconjugation Type
6.1. Introduction
6.2. Oligonucleotide Bioconjugation
6.2.1. Double-Stranded Oligonucleotides
6.2.2. Single-Stranded Oligonucleotides
6.3. Peptide Bioconjugation
6.4. Polymer Bioconjugation
6.5. Protein Bioconjugation
7. Bioconjugation Market, by Offering
7.1. Introduction
7.2. Reagents & Kits
7.3. Services
7.3.1. ADC Process Development
7.3.2. Analytical development
7.3.3. Drug Substance Manufacturing
7.3.4. Early Development Bioconjugate Services
7.3.5. Payload & Linker Manufacturing
7.3.6. Targeting Agent or Carrier Protein Services
8. Bioconjugation Market, by Technique
8.1. Introduction
8.2. Amide Bond Formation
8.3. Bio-orthogonal Reactions
8.4. Click Chemistry
8.5. Enzymatic Methods
8.6. Thiol-Maleimide Coupling
9. Bioconjugation Market, by Type
9.1. Introduction
9.2. Natural Bioconjugates
9.3. Synthetic Bioconjugates
10. Bioconjugation Market, by End User
10.1. Introduction
10.2. Academic & Research Institutions
10.3. Biotechnology Companies
10.4. Contract Research Organizations
10.5. Pharmaceutical Companies
11. Bioconjugation Market, by Applications
11.1. Introduction
11.2. Diagnostics
11.3. Research and Development
11.4. Therapeutic
11.4.1. Antibiotics
11.4.2. Monoclonal Antibodies
11.4.3. Vaccines
12. Bioconjugation Market, by Therapeutic Areas
12.1. Introduction
12.2. Cardiovascular Disorders
12.3. Immunology
12.4. Infectious Diseases
12.5. Oncology
13. Americas Bioconjugation Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Bioconjugation Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Bioconjugation Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2023
16.2. FPNV Positioning Matrix, 2023
16.3. Competitive Scenario Analysis
16.3.1. Lonza expands U.S. biologics capacity with USD 1.2 Billion acquisition of Roche's vacaville site
16.3.2. Abzena expands partnership with proteoNic to standardize 2G UNic technology
16.3.3. Abzena invests USD 5 million to enhance bioconjugation and ADC capacities at bristol facility
16.3.4. WuXi XDC Commences construction of Singapore facility to boost bioconjugate development
16.3.5. AstraZeneca's strategic acquisition of Fusion Pharmaceuticals to enhance Radioconjugate cancer therapies
16.3.6. Samsung Biologics and LegoChem Biosciences collaborate on antibody-drug conjugate development
16.3.7. Novo holdings strategic acquisition of Catalent to enhance bioconjugation capabilities
16.3.8. OnCusp Therapeutics garners USD 100M Series A funding for advancing CUSP06 ADC and expanding oncology innovations
16.3.9. Piramal Pharma Solutions boosts global bioconjugation capabilities with Pound 45 million ADC expansion
16.3.10. GeneQuantum and BioMap partner to revolutionize ADC therapeutics with AI-driven bioconjugation
16.3.11. Nona Biosciences and GeneQuantum partner to advance next-gen bioconjugate drug discovery
16.4. Strategy Analysis & Recommendation
16.4.1. WuXi AppTec Co., Ltd
16.4.2. Lonza Group AG
16.4.3. Merck KGaA
16.4.4. Thermo Fisher Scientific Inc.
List of Figures
FIGURE 1. BIOCONJUGATION MARKET MULTI-CURRENCY
FIGURE 2. BIOCONJUGATION MARKET MULTI-LANGUAGE
FIGURE 3. BIOCONJUGATION MARKET RESEARCH PROCESS
FIGURE 4. BIOCONJUGATION MARKET SIZE, 2023 VS 2030
FIGURE 5. GLOBAL BIOCONJUGATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL BIOCONJUGATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL BIOCONJUGATION MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
FIGURE 11. GLOBAL BIOCONJUGATION MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2023 VS 2030 (%)
FIGURE 13. GLOBAL BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL BIOCONJUGATION MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 15. GLOBAL BIOCONJUGATION MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL BIOCONJUGATION MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 17. GLOBAL BIOCONJUGATION MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. GLOBAL BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2023 VS 2030 (%)
FIGURE 19. GLOBAL BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. GLOBAL BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2023 VS 2030 (%)
FIGURE 21. GLOBAL BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. AMERICAS BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. AMERICAS BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. UNITED STATES BIOCONJUGATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 25. UNITED STATES BIOCONJUGATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 27. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 30. BIOCONJUGATION MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 31. BIOCONJUGATION MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. BIOCONJUGATION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BIOCONJUGATION MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOCONJUGATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. BIOCONJUGATION MARKET DYNAMICS
TABLE 7. GLOBAL BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOCONJUGATION MARKET SIZE, BY DOUBLE-STRANDED OLIGONUCLEOTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOCONJUGATION MARKET SIZE, BY SINGLE-STRANDED OLIGONUCLEOTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOCONJUGATION MARKET SIZE, BY PEPTIDE BIOCONJUGATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOCONJUGATION MARKET SIZE, BY POLYMER BIOCONJUGATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOCONJUGATION MARKET SIZE, BY PROTEIN BIOCONJUGATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOCONJUGATION MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOCONJUGATION MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOCONJUGATION MARKET SIZE, BY ADC PROCESS DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOCONJUGATION MARKET SIZE, BY ANALYTICAL DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOCONJUGATION MARKET SIZE, BY DRUG SUBSTANCE MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOCONJUGATION MARKET SIZE, BY EARLY DEVELOPMENT BIOCONJUGATE SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOCONJUGATION MARKET SIZE, BY PAYLOAD & LINKER MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOCONJUGATION MARKET SIZE, BY TARGETING AGENT OR CARRIER PROTEIN SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOCONJUGATION MARKET SIZE, BY AMIDE BOND FORMATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOCONJUGATION MARKET SIZE, BY BIO-ORTHOGONAL REACTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOCONJUGATION MARKET SIZE, BY CLICK CHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOCONJUGATION MARKET SIZE, BY ENZYMATIC METHODS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOCONJUGATION MARKET SIZE, BY THIOL-MALEIMIDE COUPLING, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOCONJUGATION MARKET SIZE, BY NATURAL BIOCONJUGATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOCONJUGATION MARKET SIZE, BY SYNTHETIC BIOCONJUGATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIOCONJUGATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIOCONJUGATION MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIOCONJUGATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIOCONJUGATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BIOCONJUGATION MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BIOCONJUGATION MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BIOCONJUGATION MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BIOCONJUGATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BIOCONJUGATION MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BIOCONJUGATION MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BIOCONJUGATION MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BIOCONJUGATION MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BIOCONJUGATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 83. CANADA BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 84. CANADA BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 85. CANADA BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 86. CANADA BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 87. CANADA BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 88. CANADA BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 89. CANADA BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. CANADA BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 91. CANADA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 92. CANADA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 93. MEXICO BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 94. MEXICO BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 95. MEXICO BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 96. MEXICO BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 97. MEXICO BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 98. MEXICO BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 99. MEXICO BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. MEXICO BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 101. MEXICO BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 102. MEXICO BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES BIOCONJUGATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 114. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 116. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 117. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 118. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 119. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 120. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 122. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 123. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 124. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 125. AUSTRALIA BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 126. AUSTRALIA BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 127. AUSTRALIA BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 128. AUSTRALIA BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 129. AUSTRALIA BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 130. AUSTRALIA BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 131. AUSTRALIA BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. AUSTRALIA BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 133. AUSTRALIA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 134. AUSTRALIA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 135. CHINA BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 136. CHINA BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 137. CHINA BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 138. CHINA BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 139. CHINA BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 140. CHINA BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 141. CHINA BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. CHINA BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 143. CHINA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 144. CHINA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 145. INDIA BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 146. INDIA BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 147. INDIA BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 148. INDIA BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 149. INDIA BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 150. INDIA BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 151. INDIA BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. INDIA BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 153. INDIA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 154. INDIA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 155. INDONESIA BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 156. INDONESIA BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 157. INDONESIA BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 158. INDONESIA BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 159. INDONESIA BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 160. INDONESIA BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 161. INDONESIA BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. INDONESIA BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 163. INDONESIA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 164. INDONESIA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 165. JAPAN BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 166. JAPAN BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 167. JAPAN BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 168. JAPAN BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 169. JAPAN BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 170. JAPAN BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 171. JAPAN BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 172. JAPAN BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 173. JAPAN BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 174. JAPAN BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 175. MALAYSIA BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 176. MALAYSIA BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 177. MALAYSIA BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 178. MALAYSIA BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 179. MALAYSIA BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 180. MALAYSIA BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 181. MALAYSIA BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. MALAYSIA BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 183. MALAYSIA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 184. MALAYSIA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 185. PHILIPPINES BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 186. PHILIPPINES BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 187. PHILIPPINES BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 188. PHILIPPINES BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 189. PHILIPPINES BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 190. PHILIPPINES BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 191. PHILIPPINES BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 192. PHILIPPINES BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 193. PHILIPPINES BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 194. PHILIPPINES BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 195. SINGAPORE BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 196. SINGAPORE BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 197. SINGAPORE BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 198. SINGAPORE BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 199. SINGAPORE BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 200. SINGAPORE BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 201. SINGAPORE BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. SINGAPORE BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 203. SINGAPORE BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 204. SINGAPORE BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 205. SOUTH KOREA BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 206. SOUTH KOREA BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 207. SOUTH KOREA BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 208. SOUTH KOREA BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 209. SOUTH KOREA BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 210. SOUTH KOREA BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 211. SOUTH KOREA BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 212. SOUTH KOREA BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 213. SOUTH KOREA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 214. SOUTH KOREA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 215. TAIWAN BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 216. TAIWAN BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 217. TAIWAN BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 218. TAIWAN BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 219. TAIWAN BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 220. TAIWAN BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 221. TAIWAN BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. TAIWAN BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 223. TAIWAN BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 224. TAIWAN BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 225. THAILAND BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 226. THAILAND BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 227. THAILAND BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 228. THAILAND BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 229. THAILAND BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 230. THAILAND BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 231. THAILAND BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. THAILAND BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 233. THAILAND BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 234. THAILAND BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 235. VIETNAM BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 236. VIETNAM BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 237. VIETNAM BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 238. VIETNAM BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 239. VIETNAM BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 240. VIETNAM BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 241. VIETNAM BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 242. VIETNAM BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 243. VIETNAM BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 244. VIETNAM BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 256. DENMARK BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 257. DENMARK BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 258. DENMARK BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 259. DENMARK BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 260. DENMARK BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 261. DENMARK BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 262. DENMARK BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 263. DENMARK BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 264. DENMARK BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 265. DENMARK BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 266. EGYPT BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 267. EGYPT BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 268. EGYPT BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 269. EGYPT BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 270. EGYPT BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 271. EGYPT BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 272. EGYPT BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. EGYPT BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 274. EGYPT BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 275. EGYPT BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 276. FINLAND BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 277. FINLAND BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 278. FINLAND BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 279. FINLAND BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 280. FINLAND BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 281. FINLAND BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 282. FINLAND BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 283. FINLAND BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 284. FINLAND BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 285. FINLAND BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 286. FRANCE BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 287. FRANCE BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 288. FRANCE BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 289. FRANCE BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 290. FRANCE BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 291. FRANCE BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 292. FRANCE BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 293. FRANCE BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 294. FRANCE BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 295. FRANCE BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 296. GERMANY BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 297. GERMANY BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 298. GERMANY BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 299. GERMANY BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 300. GERMANY BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 301. GERMANY BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 302. GERMANY BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 303. GERMANY BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 304. GERMANY BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 305. GERMANY BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 306. ISRAEL BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 307. ISRAEL BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 308. ISRAEL BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 309. ISRAEL BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 310. ISRAEL BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 311. ISRAEL BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 312. ISRAEL BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 313. ISRAEL BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 314. ISRAEL BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 315. ISRAEL BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 316. ITALY BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 317. ITALY BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 318. ITALY BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 319. ITALY BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 320. ITALY BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 321. ITALY BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 322. ITALY BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 323. ITALY BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 324. ITALY BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 325. ITALY BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 326. NETHERLANDS BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 327. NETHERLANDS BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 328. NETHERLANDS BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 329. NETHERLANDS BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 330. NETHERLANDS BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 331. NETHERLANDS BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 332. NETHERLANDS BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 333. NETHERLANDS BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 334. NETHERLANDS BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 335. NETHERLANDS BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 336. NIGERIA BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 337. NIGERIA BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 338. NIGERIA BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 339. NIGERIA BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 340. NIGERIA BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 341. NIGERIA BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 342. NIGERIA BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 343. NIGERIA BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 344. NIGERIA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 345. NIGERIA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 346. NORWAY BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 347. NORWAY BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 348. NORWAY BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 349. NORWAY BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 350. NORWAY BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 351. NORWAY BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 352. NORWAY BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 353. NORWAY BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 354. NORWAY BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 355. NORWAY BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 356. POLAND BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
TABLE 357. POLAND BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
TABLE 358. POLAND BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 359. POLAND BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 360. POLAND BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 361. POLAND BIOCONJUGATION MARKET SIZE, BY TYPE, 20

Companies Mentioned

  • AbbVie Inc.
  • Abcam plc by Danaher Corporation
  • Abzena Limited
  • Agilent Technologies, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bio-Techne Corporation
  • Biocon Limited
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Charles River Laboratories International, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Innovagen AB
  • Johnson & Johnson Services Inc
  • Lonza Group AG
  • Merck KGaA
  • Pfizer Inc.
  • Sanofi S.A.
  • Sartorius AG
  • Sorrento Therapeutics, Inc.
  • Sutro Biopharma, Inc.
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages196
PublishedMarch 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 9.06 Billion
Forecasted Market Value ( USD ) by 2030 $ 18.2 Billion
Compound Annual Growth Rate12.1%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

DNA Microarray Market Size, Share & Trends Analysis Report By Type (Complementary DNA Microarrays, Oligonucleotide DNA Microarrays), By Application (Gene Expression Analysis, Genotyping), By End Use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

DNA Microarray Market Size, Share & Trends Analysis Report By Type (Complementary DNA Microarrays, Oligonucleotide DNA Microarrays), By Application (Gene Expression Analysis, Genotyping), By End Use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From
Synthetic Biology Market by Tools (Oligonucleotides, Enzymes, Synthetic Cells), Technology (Sequencing, Bioinformatics), Applications (Drug Discovery, Tissue Regeneration, Biofuel, Food, Agriculture, Consumer Care, Environmental) - Global Forecast to 2029 - Product Image

Synthetic Biology Market by Tools (Oligonucleotides, Enzymes, Synthetic Cells), Technology (Sequencing, Bioinformatics), Applications (Drug Discovery, Tissue Regeneration, Biofuel, Food, Agriculture, Consumer Care, Environmental) - Global Forecast to 2029

  • Report
  • 537 Pages
  • Global
From
Antisense Oligonucleotide Therapeutics - Pipeline Insight, 2024 - Product Image

Antisense Oligonucleotide Therapeutics - Pipeline Insight, 2024

  • Drug Pipelines
  • 50 Pages
  • Global
From
Innovation Insights: Anti-sense Oligonucleotides - Product Image

Innovation Insights: Anti-sense Oligonucleotides

  • Report
  • 51 Pages
  • Global
From
Bioconjugation Market by Product (Consumables, Instruments (Chromatography, Spectrometry)), Service (Conjugation, Analytical), Technique (Chemical, Click Chemistry), Biomolecule (Antibodies), Application (Therapeutics (ADC), R&D) - Global Forecast to 2029 - Product Image

Bioconjugation Market by Product (Consumables, Instruments (Chromatography, Spectrometry)), Service (Conjugation, Analytical), Technique (Chemical, Click Chemistry), Biomolecule (Antibodies), Application (Therapeutics (ADC), R&D) - Global Forecast to 2029

  • Report
  • 683 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.